MSD in the UK
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
MSD in the UK
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
About ADEMPAS
ADEMPAS® (riociguat) /
Products /
Root /

About ADEMPAS® (riociguat)

Prescribing Information

ADEMPAS is currently reimbursed by NHS England for CTEPH patients in FC II and III, and for PAH patients in FC III.

Mode of action

ADEMPAS has a dual mode of action. It sensitises sGC to endogenous Nitric Oxide (NO) by stabilising the NO-sGC binding.1

  • Normally, NO binds to and stimulates sGC2
  • In many PH patients NO is depleted due to endothelial dysfunction3
  • NO deficiency results in sGC being understimulated3
  • sGC facilitates cyclic guanosine monophosphate (cGMP) synthesis1
  • ADEMPAS stimulates sGC independently of NO1
  • ADEMPAS also sensitises sGC to endogenous NO by stabilising the NO-sGC binding3

NO = Nitric Oxide; sGC = soluble Guanylate Cyclase; cGMP = cyclic Guanosine Monophosphate; GTP = Guanosine Triphosphate

How does ADEMPAS work?

  • ADEMPAS acts on the NO pathway by stimulating sGC. When NO binds to sGC, cGMP is synthesised
  • ADEMPAS has a dual mode of action, increasing cGMP levels by both:
    • sensitising sGC to endogenous NO
    • directly stimulating sGC independently of NO

Why is this important?

  • Intracellular cGMP has an important part in regulating processes that influence vascular tone, proliferation, fibrosis and inflammation
  • Pulmonary hypertension is associated with endothelial dysfunction, impaired synthesis of NO, and insufficient stimulation of the NO-sGC-cGMP pathway
  • ADEMPAS restores the NO-sGC-cGMP pathway, resulting in an improvement of pulmonary vascular hemodynamics and an increase in exercise ability

ADEMPAS is a member of a class of therapeutic agents called soluble guanylate cyclase stimulators (sGC stimulators), and is used for the treatment of Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

In PAH, ADEMPAS is licenced as monotherapy or in combination with endothelin receptor antagonists (ERA’s), for the treatment of adult patients with PAH with WHO Functional Class (FC) II to III to improve exercise capacity.

In CTEPH, ADEMPAS is licenced for the treatment of adult patients with WHO functional class II to III with:

  • inoperable CTEPH
  • persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity

References

  1. O’Callaghan DS, Savale L, Montani D, et al. Treatment of pulmonary arterial hypertension with targeted therapies. Nature Rev Drug Cardiol. 2011;8:526–538.
  2. Stasch J-P, Pacher P, Evgenov OV, et al. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation. 2011;123:2263–2273.
  3. ADEMPAS Summary of Product Characteristics.

Supporting documentation

Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-ADE-00253 | Date of Preparation: February 2020